NASDAQ:IDXGInterpace Diagnostics Group Stock Price, Forecast & News

Interpace Diagnostics Group's stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDXG shares have decreased by 31.7% and is now trading at $4.41. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Interpace Diagnostics Group.

Interpace Diagnostics Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Interpace Diagnostics Group.

Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its earnings results on Thursday, June, 25th. The business services provider reported ($2.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.24) by $1.08. The business services provider had revenue of $9.20 million for the quarter, compared to the consensus estimate of $8.95 million. Interpace Diagnostics Group had a negative net margin of 110.80% and a negative return on equity of 119.88%. View Interpace Diagnostics Group's earnings history.

Interpace Diagnostics Group issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, June, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.6-6 million, compared to the consensus revenue estimate of $6.27 million.

5 Wall Street analysts have issued 1 year price objectives for Interpace Diagnostics Group's shares. Their forecasts range from $3.00 to $12.00. On average, they expect Interpace Diagnostics Group's stock price to reach $8.81 in the next year. This suggests a possible upside of 99.8% from the stock's current price. View analysts' price targets for Interpace Diagnostics Group.

News stories about IDXG stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the business services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Interpace Diagnostics Group.

Interpace Diagnostics Group saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 99,100 shares, a decline of 18.6% from the May 31st total of 121,700 shares. Based on an average trading volume of 80,900 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.5% of the company's shares are short sold. View Interpace Diagnostics Group's Current Options Chain.

Some companies that are related to Interpace Diagnostics Group include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY) and Cross Country Healthcare (CCRN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), AT&T (T), Trevena (TRVN), Genocea Biosciences (GNCA) and AbbVie (ABBV).

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IDXG stock can currently be purchased for approximately $4.41.

Interpace Diagnostics Group has a market capitalization of $17.80 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. Interpace Diagnostics Group employs 176 workers across the globe.

The official website for Interpace Diagnostics Group is www.interpace.com.

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]isongroup.com.